BioNexus Gene Lab Corp (BGLC) director reports holding 0 common shares
Rhea-AI Filing Summary
BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul reports direct ownership of 0 shares of common stock as of 2023-12-11. The entry is presented as a holding record, with no purchase, sale, or derivative transactions reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bin Abdul Hamid Muhammad Azrul
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | COMMON STOCK | -- | -- | -- |
Holdings After Transaction:
COMMON STOCK — 0 shares (Direct)
Key Figures
Common stock holdings: 0.0000 shares
Holding entries reported: 1 entry
Net buy/sell shares: 0 shares
3 metrics
Common stock holdings
0.0000 shares
Direct ownership after reported holding entry as of 2023-12-11
Holding entries reported
1 entry
Number of holding rows in the insider report
Net buy/sell shares
0 shares
Transaction summary net buy/sell direction reported as neutral
Key Terms
COMMON STOCK, total_shares_following_transaction, direct_or_indirect
3 terms
COMMON STOCK financial
"security_title: "COMMON STOCK""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
direct_or_indirect financial
"Field direct_or_indirect is reported as "D" for direct"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did BioNexus Gene Lab Corp (BGLC) director Bin Abdul Hamid Muhammad Azrul report in this filing?
Bin Abdul Hamid Muhammad Azrul reported direct ownership of 0 shares of BioNexus Gene Lab Corp common stock as of 2023-12-11, using a holding entry with no associated purchase, sale, or derivative transaction activity.
What type of security is disclosed for BioNexus Gene Lab Corp (BGLC) in this report?
The report discloses holdings in COMMON STOCK of BioNexus Gene Lab Corp. The security title is explicitly stated as common stock, and the total shares reported following the holding entry are 0.0000.
What is the relevant date for the BioNexus Gene Lab Corp (BGLC) director’s reported holdings?
The holding entry for the director’s BioNexus Gene Lab Corp common stock position is dated 2023-12-11. On that date, the total shares of common stock reported as directly owned were 0.0000.
Does this BioNexus Gene Lab Corp (BGLC) insider report show any buy or sell transactions?
No buy or sell transactions are shown; the filing lists a holding entry only. The transaction summary indicates no purchases, sales, exercises, or gifts, and net buy/sell shares are reported as 0.